Kmart Corp. agreed to pay $35.3 million to the federal government and a number of states to settle a whistleblower lawsuit.
A judge overturned a $150 million verdict against AbbVie, the first resulting from lawsuits claiming the company fraudulently misrepresented the risks of AndroGel.
Ocular Therapeutix Inc. said the U.S. Securities and Exchange Commission (SEC) issued a subpoena seeking information about the company’s eye-pain drug Dextenza.
Novartis drug Tasigna is approved by FDA as first CML therapy with Treatment-free Remission data in its label
Novartis announced that the FDA approved the inclusion of Treatment-free Remission data in the Tasigna (nilotinib) U. S. product label.
Canadian drugmaker Valeant Pharmaceuticals International Inc. said the U.S. Food and Drug Administration approved Lumify drop to treat eye redness.
Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.
Shares of Agile Therapeutics plunged more than 62 percent in early trading after the company announced that the U.S. FDA rejected its low-dose hormonal contraceptive patch called Twirla.
The U.S. Food and Drug Administration said it plans to let medical device makers report less serious malfunctions of some devices on a quarterly basis to cut down on repeated reviews of common problems.
The U.S. FDA granted priority review for Novartis’ Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.
Roche will buy U.S. cancer drugmaker Ignyta Inc. for $1.7 billion to broaden the Swiss drugmaker’s oncology portfolio globally.
California’s top court opened the door for consumers to sue Novartis AG and other makers of brand-name pharmaceutical products over injuries blamed on generic versions of the drugs manufactured by other companies.
La Jolla Pharmaceutical said the U.S. Food and Drug Administration approved its drug Giapreza to treat dangerously low blood pressure.
Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy
Janssen Biotech Inc. entered into a worldwide collaboration and license agreement with Legend Biotech USA Inc. and Legend Biotech Ireland Limited to develop, manufacture and commercialize a chimeric antigen receptor (CAR) T-cell drug candidate, LCAR-B38M, which specifically targets the B-cell maturation antigen.
SAB Therapeutics announced its first-in-human trial of new immunotherapy approach has shown efficacy in antibiotic-resistant bacteria based on a recent paper published online in Clinical Infectious Diseases.
FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with Inlyta in Advanced Renal Cell Carcinoma
Merck KGaA and Pfizer Inc. announced that the U.S. FDA granted Breakthrough Therapy Designation for avelumab in combination with Inlyta (axitinib) treatment-naïve patients with advanced renal cell carcinoma.
The U.S. FDA approved Merck’s and Pfizer’s Steglatro (ertugliflozin), a sodium-glucose co-transporter 2 (SGLT2)- inhibitor, which will square off against established drugs in the market.
Life expectancy in the United States dipped in 2016 as the number of deaths due to opioid drug overdoses surged and total drug overdose deaths rose 21 percent to 63,600, the U.S. Centers for Disease Control and Prevention said.
There is a fundamental disconnect between companies and consumers: Healthcare brands often fail to address patients’ emotional journeys.
Swiss drugmaker Roche won approvals for two cancer drugs in Europe and the United States, shoring up its position in new medicines as it braces for falling sales of older products.
The FDA will fast track the review of Australian drug developer Mesoblast Ltd.’s cell therapy treatment for heart failure patients under a new designation rolled out in December 2016.